Skip to main
CTSO

CytoSorbents (CTSO) Stock Forecast & Price Target

CytoSorbents (CTSO) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

CytoSorbents Corp has demonstrated a strong financial performance, with fourth-quarter gross margins expected to range between 73% and 75%, and a full-year gross margin rising to approximately 72%, highlighting the company’s operational efficiencies and growth strategy. The company reported $9.5 million in revenue, reflecting a 10% year-over-year increase, driven by successful distributor sales and improved manufacturing efficiencies, while also achieving significant progress with its DrugSorb-ATR product. Management's strategic financial maneuvers, such as amending the credit agreement to enhance liquidity, combined with positive clinical data and expanding evidence for their products in critical care, further bolster the positive outlook for CytoSorbents's stock.

Bears say

CytoSorbents Corp reported fourth-quarter revenue of approximately $9.2 million, showing no growth compared to the previous year, while full-year revenue reached about $37 million, reflecting a modest increase of 4%. The company faces challenges due to patient imbalances observed in the initial phase of its U.S. operations, contributing to a lack of momentum in revenue growth. Furthermore, shares are perceived to be trading at a distressed valuation that does not align with underlying financial fundamentals.

CytoSorbents (CTSO) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CytoSorbents and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CytoSorbents (CTSO) Forecast

Analysts have given CytoSorbents (CTSO) a Buy based on their latest research and market trends.

According to 2 analysts, CytoSorbents (CTSO) has a Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CytoSorbents (CTSO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.